Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)
You may also be interested in...
Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
Shionogi will clear up cash by turning over global rights to its integrase inhibitor portfolio to its joint venture partner in exchange for royalties and equity in ViiV.
Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
Shionogi will clear up cash by turning over global rights to its integrase inhibitor portfolio to its joint venture partner in exchange for royalties and equity in ViiV.
Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
Anticipating the loss of royalties from Crestor in the next five years, Japanese innovator Shionogi continues its globalization process with a U.K. headquarters to pursue development of its late-stage research pipeline in Europe.